MyBlueDots

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per share. All of the shares are being offered by Amylyx. In addition, Amylyx has granted the underwriter a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price per share, less underwriting dis

DUBLIN–(BUSINESS WIRE)–The “Preclinical Contract Research Organizations – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Preclinical Contract Research Organizations was estimated at US$7.1 Billion in 2023 and is projected to reach US$11.3 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed bus

GLASGOW, Scotland–(BUSINESS WIRE)– #Chemify–Chemify hires biopharma veteran Dr. Alastair Leighton as Chief Operating Officer.

MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. “We are thrilled to have Paul assume the role of Chief Executive Officer,” said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. “Having worked very clo

JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative treatments for patients with age-related macular degeneration (AMD). This relationship, initiated in 2024, represents a major step forward by bringing together Bausch + Lomb’s extensive expertise in ophthalmology with Character Bio’s integrated patient data platform a

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development. “The most important predicter of successful drug development is a team of people who have successfully developed a therapy from discovery to regulatory approval,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto.

SAN DIEGO–(BUSINESS WIRE)—- $ARCT #ClinicalTrial–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the initiation of the Company’s Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H

BASEL, Switzerland & PHILADELPHIA–(BUSINESS WIRE)–RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively lic

WALTHAM, Mass.–(BUSINESS WIRE)–Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx test for Molecular Residual Disease (MRD) detection in anal squamous cell carcinoma (ASCC) patients. NavDx, Naveris’ proprietary flagship blood test, is the first and only clinically validated circulating tumor TTMV®-HPV DNA blood test that provides a non-invasive and precise method that can detect MRD before th